

1Pr PREVENTION	2Ep EPIDEMIOLOGY & CANCER REGISTRATION	3Sc SCREENING	4Tr TREATMENT & CLINICAL ASPECTS	5Mv MACRO SOCIAL AND ECONOMIC VARIABLES
<p><u>Lifestyle</u></p> <p>01. Consumption of fruit and vegetables *</p> <p>02. Consumption of alcohol *</p> <p>03. Body Mass Index distribution in the population *</p> <p>04. Physical activity *</p> <p>05. Tobacco survey: prevalence of</p> <p>a. tobacco smokers among adults</p> <p>b. tobacco smokers among 10-14 year olds</p> <p>c. ex-smokers</p> <p><u>Environment & Occupational risk</u></p> <p>d. exposure to environmental tobacco smoke (ETS)</p> <p>06. Exposure to sun radiation</p> <p>07. PM10 (particulate matter = 10µ³) emissions *</p> <p>08. Indoor exposure to radon</p> <p>09. Prevalence of occupational exposure to carcinogens</p> <p>10. Exposure to asbestos: mesothelioma incidence and mortality trends</p> <p><u>Medicaments</u></p> <p>11. Prevalence of use of hormonal replacement treatment drugs *</p>	<p>1. Population covered by high quality Cancer Registries</p> <p>2. Cancer incidence rates, trends and projections *</p> <p>3. Cancer relative survival rates, trends and projections *</p> <p>4. Cancer prevalence proportions, trends and projections *</p> <p>5. Cancer mortality rates, trends, projections and person-years of life lost due to cancer *</p> <p>6. Stage at diagnosis: percentage of</p> <p>a. cases with early diagnosis</p> <p>b. cases with a metastatic test</p>	<p><u>Screening examinations</u></p> <p>1. Percentage of women that have undergone a mammography (breast cancer)</p> <p>2. Percentage of women that have undergone a cervical cytology examination (cervical cancer)</p> <p>3. Percentage of persons that have undergone a colo-rectal cancer screening test</p> <p><u>National evaluation in HMP of organized mass screening process indicators</u></p> <p>4a. Organized screening coverage</p> <p>4b. Screening recall rate</p> <p>4c. Screening detection rate</p> <p>4d. Screening localized cancers</p> <p>4e. Screening positive predictive value</p> <p>4f. Screening benign/malignant biopsy ratio</p> <p>4g. Screening interval cancers</p> <p>4h. Screening specificity</p>	<p><u>Health system delay</u></p> <p>1. Delay of cancer treatment (pilot studies)</p> <p><u>Resources</u></p> <p>2. Percentage of radiation systems in the population</p> <p>3. Percentage of diagnostic Computed Axial Tomographies (CTs) in the population</p> <p>4. Percentage of Positron Emission Tomographies (PETs) on population (for future)</p> <p>5. Percentage of magnetic resonances on population (for future)</p> <p><u>Treatment</u></p> <p>6. Compliance with best oncology practice</p> <p><u>Palliative care</u></p> <p>7. Use of morphine in cancer patients</p> <p>8. Percentage of patients receiving palliative radiotherapy</p>	<p><u>Social indicators</u></p> <p>01. Educational level attained *</p> <p>02. Income by decile *</p> <p>03. Gini's index *</p> <p><u>Macro economic indicators</u></p> <p>04. Gross Domestic Product *</p> <p>05. Total Social Expenditure *</p> <p>06. Total National Expenditure on Health *</p> <p>07. Total Public Expenditure on Health *</p> <p>08. Anti-tobacco regulations</p> <p>09a. Public expenditure for cancer prevention on anti-tobacco activity</p> <p>09b. Total expenditure for population-based cancer registries</p> <p>09c. Total expenditure on organized cancer screening programmes</p> <p>09d. Public expenditure on cancer drugs *</p> <p>09e. Total expenditure on cancer research</p> <p>09f. Estimated cost for a cancer patient</p> <p><u>Demographic indicators</u></p> <p>10. Age distribution in 2010, 2020 and 2030 *</p> <p>11. Life-table quantities *</p>

* Connected with other HMP projects

		HIGH PRIORITY	MEDIUM PRIORITY
LOW COSTS or NO NEW COSTS	Indicators already available	<p>Population covered by high quality Cancer Registry</p> <p>Cancer incidence rates, trends and projections</p> <p>Cancer survival rates, trends and projections</p> <p>Cancer prevalence proportions, trends and projections</p> <p>Cancer mortality rates, trends, projections and person-years life lost due to cancer</p> <p>Gross Domestic Product</p> <p>Total Public Expenditure on Health</p>	<p>Exposure to asbestos: mesothelioma incidence and mortality trends</p> <p>Education level attained</p> <p>Income by decile</p> <p>Gini's index</p> <p>Total Social Expenditure</p> <p>Total National Expenditure on Health</p> <p>Age distribution in 2010-20-30</p> <p>Life-table quantities</p>
	Sources already available	<p>Organized screening coverage</p> <p>Anti-tobacco regulations</p>	<p>National evaluation in HMP of the organized screening process indicators</p> <p>Screening recall rate, Screening detection rate, Screening localized cancers, Screening positive predictive value, Screening benign/malignant biopsy ratio, Screening interval cancers, Screening specificity</p>
MEDIUM COSTS	Databank updates	<p>Prevalence of occupational exposure to carcinogens</p>	<p>PM10 (particulate matter = 10μ^3) emissions</p>
	Surveys	<p>Health survey</p> <p>Consumption of fruit and vegetables</p> <p>Consumption of alcohol</p> <p>Body Mass Index distribution in the population</p> <p>Physical activity</p> <p>Tobacco survey: prevalence of current tobacco smokers among adults, prevalence of tobacco smokers among 10-14 year olds, prevalence of ex-smokers, prevalence of exposure to environmental tobacco smoke (ETS)</p> <p>Exposure to sun radiation</p> <p>Percentage of women that have undergone a mammography (breast cancer)</p> <p>Percentage of women that have undergone a cervical citology examination (cervical cancer)</p> <p>Percentage of persons that have undergone a colo-rectal cancer screening test</p> <p>Other surveys</p> <p>Percentage of radiation systems on population</p> <p>Percentage of diagnostic CT (Computed Axial Tomography) on population</p> <p>Proportion of patients treated with palliative radiotherapy</p> <p>Estimated cost for a cancer patient</p>	<p>Other surveys</p> <p>Prevalence of use of hormonal replacement treatment drugs</p> <p>Percentage of PETs (Positron Emission Tomography) on population (for future)</p> <p>Percentage of magnetic resonances on population (for future)</p> <p>Use of morphine in cancer patients</p> <p>Public expenditure for cancer prevention on anti-tobacco activity</p> <p>Total expenditure for population-based Cancer Registries</p> <p>Total expenditure on organized cancer screening programmes</p> <p>Public Expenditure on cancer drugs</p> <p>Total expenditure on cancer research</p>
HIGH COST	CRs	<p>Stage at diagnosis: percentage of cases with early diagnosis and with a metastatic test</p> <p>Delay of cancer treatment: pilot studies</p> <p>Compliance with best oncology practice</p>	
	Other		<p>Indoor exposure to radon</p>